News
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Correction of a release from 14/02/2024, 07:51 CET/CEST - AMADEUS FIRE AG: Preliminary figures for the 2023 financial year
Amadeus Fire AG reports record sales and operating EBITA in 2023, with a growth rate of 8.7% and 3.5% respectively. Company overcomes challenges in Personnel Services segment -
-
COMMUNIQUÉ DE PRESSE
Original-Research: Multitude SE (von NuWays AG): BUY
Multitude SE's research update anticipates continued growth as it aims for €30m net income in FY26. With a focus on high-demand loan sectors, controlled risks, and premium loans, the company showcases a promising outlook for investors -
-
COMMUNIQUÉ DE PRESSE
Mirabelle Introduces Heydey Fitness
Mirabelle, a senior living community managed by The Arbor Company, introduces cutting-edge Heydey Fitness program using AI-powered equipment to enhance resident wellness and strength. The technology benefits seniors with personalized fitness plans -
-
COMMUNIQUÉ DE PRESSE
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential
